Gliomatosis cerebri is a rare and serious disease associated with the formation of multiple gliomas, which are tumors that arise from glial cells in the brain. These cells perform important functions, including supporting and protecting neurons, as well as participating in the metabolism of nervous tissue. Gliomas can cause a variety of neurological symptoms, including headaches, seizures, disturbances of consciousness, and other brain functions, depending on the location and size of the tumor. This disease tends to be more aggressive and can lead to a deterioration in the quality of life of patients, as well as death. It is important to note that gliomatosis can manifest itself in different forms, including both high-grade and low-grade tumors, which further complicates its diagnosis and treatment.
History of the disease and interesting historical facts
Gliomatosis has attracted the attention of researchers over the last hundred years, beginning with the first descriptions of gliomas in the 1920s. Discoverers of this disease, such as Nils Reifenstein, played a significant role in shaping the modern understanding of gliomas and their classification. The etymology of the term "glioma" goes back to the Greek word "glia", meaning "glue", reflecting the main function of glial cells in supporting neurons. Research on stereotactic surgery and radiotherapy of gliomas was carried out in the 1970s, which opened up new horizons in the treatment of the disease. Since then, much research has been carried out aimed at elucidating the molecular mechanisms underlying the tumor process, as well as developing new diagnostic and therapeutic methods.
Epidemiology
According to global statistical studies, gliomatosis cerebri accounts for approximately 25% of all central nervous system tumors. In the United States, the incidence is estimated at 5 cases per 100,000 people per year. Men are more susceptible to this disease than women, with a ratio of 1.5:1. While the age group of 45-70 years is most susceptible, there are rare cases where gliomas are diagnosed in children and young adults. According to the World Health Organization, the average survival rate of patients with high-grade gliomas is less than 15 months, which emphasizes the seriousness of this disease.
Genetic predisposition to this disease
Current research suggests that gliomatosis may be associated with certain genetic mutations, including changes in genes such as TP53, IDH1, and those encoding proteins involved in the cell cycle and apoptosis. Genetic changes involving chromosomes 1p and 19q are also associated with a high incidence of gliomas, particularly in patients with oligodendrogliomas. It is important to note that a family history may indicate a genetic predisposition, although most cases of the disease are sporadic. Research is highlighting the importance of genetic testing for more accurate diagnosis and prognosis.
Risk factors for the development of this disease
Risk factors for gliomatosis are varied and include both physical and chemical components. Physical factors include exposure to radiation, which has been associated with an increased risk of developing gliomas. Chemicals such as aminotransferases and certain pesticides may also cause changes in brain cells and, therefore, gliomatosis. Potential links to viral infections such as herpes simplex virus have also been discussed, but these studies require further study. Lifestyle and environmental factors, including diet and alcohol consumption, may also influence the incidence of the disease.
Diagnosis of this disease
Diagnosis of gliomatosis involves a comprehensive approach to identifying symptoms and conducting laboratory tests. The main clinical symptoms range from neurological disorders to general deterioration. Laboratory tests may include blood tests, but their specificity for this pathology is limited. Radiological examination, in particular magnetic resonance imaging (MRI), is a key diagnostic method that allows visualization of the tumor size and location. Other methods, such as positive emission tomography (PET), can also be useful. Differential diagnosis involves excluding other neurological diseases, such as metastatic tumors or aneurysms.
Treatment
Treatment of gliomatosis cerebri requires an individual approach and may include a combination of surgical, pharmacological and radiotherapeutic methods. Surgical intervention includes tumor resection, which can lead to improved symptoms and survival, but is not always possible due to the location of the tumor. Pharmacological treatment often includes chemotherapy drugs, such as temozolomide, which is used in the case of aggressive forms of tumors. Palliative care is also important to improve the patient's quality of life. The latest research in the field of immunotherapy and targeted therapy opens up new horizons in the treatment of this disease.
List of medications used to treat this disease
- Temozolomide
- Lomustine
- Sorefenib
- Vinokalkalou
- Selective VEGF induction
- Tarakurin
Disease monitoring
Monitoring of the patient with gliomatosis is critical and includes regular radiological examinations and clinical observation. Monitoring steps may vary depending on the type and stage of the disease, but a general recommendation is to perform MRI every 3-6 months for the first year after treatment. Prognosis may vary depending on the type of glioma, with high-grade tumors having a worse prognosis than low-grade tumors. Complications are variable, but the most common are tumor recurrence and complications related to neurosurgery.
Age-related features of the disease
Gliomatosis may present differently depending on the age group of the patient. Children tend to have lower-grade tumors such as pilomicrocastrosmas with a better prognosis, while adults are more likely to have high-grade gliomas that require aggressive treatment. Older patients may have a slower progression of symptoms, but the complexity of treatment and overall comorbidity may worsen the outcome of therapy.
Questions and Answers
- What are the main symptoms of gliomatosis? The main symptoms include headaches, seizures, visual impairment and cognitive impairment.
- What methods are used to treat gliomatosis? Treatment includes surgery, chemotherapy and radiotherapy.
- Can gliomatosis be prevented? Complete prevention is impossible, but reducing risk factors, such as avoiding radiation, may help.
- What is the life expectancy after diagnosis of gliomatosis? The average survival rate is less than 15 months, but this depends on the type of tumor and treatment methods.
- Can gliomatosis occur in children? Yes, gliomatosis can also occur in children, although more favorable forms of tumors are usually encountered.
Dr. Oleg Korzhikov, an oncology specialist, recommends that patients with gliomatosis take symptoms seriously and do not delay a visit to the doctor if neurological disorders appear. He also notes that it is important to take all prescribed medications, as this can significantly increase the duration and quality of life. If there is a risk of a hereditary factor, genetic testing and consultation with a geneticist are recommended. Each disease is individual, so stick to an individually developed treatment plan and regular monitoring.
